Effect of Chaihu Shugan Powder on patients with gastroesophageal reflux disease and its influence on cytokine and intestinal flora levels

doi:10.3877/cma.j.issn.2095-2015.2025.06.006

Abstract

Abstract:

Objective

To investigate the clinical effect of Chaihu Shugan Powder in the treatment of gastroesophageal reflux disease (GERD), and analyze its effects on cytokines and intestinal flora.

Methods

A total of 120 GERD patients admitted to Baoji Traditional Chinese Medicine Hospital from January 2022 to December 2024 were selected as the study objects. The patients were divided into control group and study group by random number table method, with 60 cases in each group. The control group was treated with omeprazole combined with mosapride, and the study group was treated with Chaihu Shugan Powder, both groups were treated for 8 weeks. The clinical efficacy, cytokines, traditional Chinese medicine syndrome score, intestinal flora and adverse reaction were compared between the two groups.

Results

After 8 weeks of treatment, the clinical efficacy of the study group was higher than that of the control group (P<0.05), and the levels of cytokines, traditional Chinese medicine syndrome scores, Enterococcus, Yeast, and Enterobacter were all lower than those of the control group (P<0.05), while the levels of Lactobacillus, Bifidobacterium, and Bacteroides were higher than those of the control group (χ²=1.081, P=0.298).

Conclusion

Chaihu Shugan Powder has remarkable effect on GERD, and can effectively regulate cytokines and intestinal flora levels.

Key words: Gastroesophageal reflux disease, Chaihu Shugan Powder, Cytokines, Intestinal flora, Curative effect

Zhengxiang Zhang, Long Gao, Wen Li. Effect of Chaihu Shugan Powder on patients with gastroesophageal reflux disease and its influence on cytokine and intestinal flora levels[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(06): 590-593.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.06.006

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I06/590

Figures/Tables 4

References 20

[1]	ASGE Standards of Practice Committee. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations[J]. Gastrointest Endosc, 2025, 101(2): 267-284.
[2]	Slater BJ, Collings A, Dirks R, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease(GERD)[J]. Surg Endosc, 2023, 37(2): 781-806.
[3]	依力汗·依明, 艾克拜尔·艾力, 买买提·依斯热依力. 炎症因子及炎症反应在胃食管反流病发病机制中作用的研究进展[J]. 国际免疫学杂志, 2022, 45(3): 321-325.
[4]	马辉, 李飞侠. 中医辨证治疗胃食管反流的临床效果[J]. 黑龙江中医药, 2022, 51(3): 53-55.
[5]	李亚鼎, 王轶, 周秉舵, 等. 经方治疗肝胃郁热型胃食管反流病的网状Meta分析[J]. 临床消化病杂志, 2023, 35(1): 1-7.
[6]	李紫梦, 康艳楠, 罗如珍, 等. 胃食管反流病症状管理指南/共识的质量评价[J]. 中国全科医学, 2020, 23(33): 4151-4159.
[7]	中华中医药学会脾胃病分会, 李军祥, 谢胜, 等. 消化系统常见病胃食管反流病中医诊疗指南(基层医生版)[J]. 中华中医药杂志, 2020, 35(6): 2995-2998.
[8]	Slater BJ, Collings A, Dirks R, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease(GERD)[J]. Surg Endosc, 2023, 37(2): 781-806.
[9]	Dimou FM, Lidor A, Velanovich V. Commentary on the Multi-society Consensus Conference and Guideline on the Treatment of Gastroesophageal Reflux Disease(GERD)[J]. J Gastrointest Surg, 2023, 27(3): 650-652.
[10]	Mahajan R, Kulkarni R, Stoopler ET. Gastroesophageal reflux disease and oral health: A narrative review[J]. Spec Care Dentist, 2022, 42(6): 555-564.
[11]	Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0.[J]. Gut, 2024, 73(2): 361-371.
[12]	刘静怡, 韩冰, 刘希桐, 等. 胃食管反流病中西医发病机制及药物治疗研究进展[J]. 时珍国医国药, 2024, 35(3): 701-705.
[13]	贾越博, 刘林, 白光, 等. 基于数据挖掘探讨胃食管反流病中医证型与用药规律分析[J]. 世界中医药, 2022, 17(15): 2121-2126, 2134.
[14]	杨泽鹏, 方震, 蒋钰杰, 等. 柴胡疏肝散治疗功能性胃肠病的研究进展[J]. 中医药信息, 2024, 41(12): 67-71.
[15]	刘淳, 甘淳, 曹书宇. 柴胡疏肝散在胃肠疾病中的研究进展[J]. 中医临床研究, 2024, 16(27): 102-106.
[16]	刘倩. 柴胡疏肝散合左金丸治疗肝胃郁热型难治性胃食管反流病临床研究[J]. 光明中医, 2024, 39(3): 487-490.
[17]	沈子芯, 牟春燕, 周雪儿, 等. 白芍及其化学成分的药理作用研究进展[J]. 江苏中医药, 2024, 56(8): 76-79.
[18]	关徐涛, 杨鹤年, 张津铖, 等. 陈皮的化学成分和药理作用研究进展[J]. 中华中医药学刊, 2024, 42(6): 41-49
[19]	梁志涛, 李明彦, 陈晓乐, 等. 柴胡疏肝散合左金丸联合内镜下贲门松弛紧缩术治疗胃食管反流病的疗效[J]. 吉林中医药, 2024, 44(8): 955-959.
[20]	赵薇, 张亚茜, 姜宇轩, 等. 柴胡疏肝散及其加减方治疗功能性消化不良的研究进展[J]. 中国实验方剂学杂志, 2024, 30(17): 248-255.

组别	例数	临床痊愈	显效	有效	无效	总有效率
研究组	60	23(38.33)	20(33.33)	13(21.67)	4(6.67)	56(93.33)
对照组	60	20(33.33)	18(30.00)	10(16.67)	12(20.00)	38(80.00)

组别	例数	临床痊愈	显效	有效	无效	总有效率
研究组	60	23(38.33)	20(33.33)	13(21.67)	4(6.67)	56(93.33)
对照组	60	20(33.33)	18(30.00)	10(16.67)	12(20.00)	38(80.00)

组别	例数	白细胞介素-6		白细胞介素-8		肿瘤坏死因子-α
组别	例数	治疗前	治疗8周后	治疗前	治疗8周后	治疗前	治疗8周后
研究组	60	18.55±2.44	9.12±1.20^*	24.12±3.02	12.40±1.16^*	16.72±2.76	8.32±1.07^*
对照组	60	18.49±2.38	13.81±1.93^*	24.05±2.86	18.92±2.45^*	16.98±2.33	12.46±1.13^*
t值		0.136	-15.985	0.130	-18.631	-0.558	-20.607
P值		0.892	<0.0001	0.897	<0.0001	0.578	<0.0001

组别	例数	白细胞介素-6		白细胞介素-8		肿瘤坏死因子-α
组别	例数	治疗前	治疗8周后	治疗前	治疗8周后	治疗前	治疗8周后
研究组	60	18.55±2.44	9.12±1.20^*	24.12±3.02	12.40±1.16^*	16.72±2.76	8.32±1.07^*
对照组	60	18.49±2.38	13.81±1.93^*	24.05±2.86	18.92±2.45^*	16.98±2.33	12.46±1.13^*
t值		0.136	-15.985	0.130	-18.631	-0.558	-20.607
P值		0.892	<0.0001	0.897	<0.0001	0.578	<0.0001

组别	例数	反酸		胃脘隐痛		胸骨后疼痛		嗳气
组别	例数	治疗前	治疗8周后	治疗前	治疗8周后	治疗前	治疗8周后	治疗前	治疗8周后
研究组	60	4.15±1.03	1.13±0.37^*	5.11±0.63	1.63±0.30^*	2.29±0.38	1.11±0.12^*	2.50±0.43	1.21±0.14^*
对照组	60	4.12±1.06	2.63±0.56^*	5.06±0.68	2.60±0.56^*	2.34±0.30	1.46±0.19^*	2.44±0.38	1.75±0.19^*
t值		0.157	-17.311	0.418	-11.827	-0.800	-6.801	0.810	-17.723
P值		0.875	<0.0001	0.677	<0.0001	0.425	<0.0001	0.420	<0.0001

Please choose a citation manager

Content to export